Michael E. Thase, MD

Article

Nocturnal Wakefulness and Suicide

June 22, 2016

Insomnia and nightmares have been shown to increase the risk for suicidal ideation and suicide. Could simply being awake at night be a risk factor as well? Perlis et...

Educational Activity

How Does Understanding Mechanism of Action Help Clinicians Personalize Antidepressant Treatment Choices?

February 24, 2016

Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

Supplement Article

Managing Medical Comorbidities in Patients With Depression to Improve Prognosis

January 27, 2016

Educational Activity

What Are the Mechanisms of Action of Current Antidepressant Treatments?

December 23, 2015

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Educational Activity

Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

September 23, 2015

Academic Highlights

Choosing Medications for Treatment-Resistant Depression

June 24, 2015

What can you do for your patients with depression who show partial response or no response to treatment? Follow a discussion by expert faculty about how altering levels of...

Commentary

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

January 28, 2015

Academic Highlights

Overview of Vortioxetine (Brintellix)

December 24, 2014

Understand what is Vortioxetine (Brintellix), an antidepressant for major depressive disorder and treatment-resistant depression.